TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05731804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0417 600 mg; Ritonavir100 mg
Description: SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0417 600 mg; Ritonavir100 mg
Description: SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
Study: NCT06465511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive clinic
Description: During the visit, each patient will receive a personalized feedback summary, including an assessment and recommendation on managing physical and psychological symptoms, an evaluation and recommendation on dietary advice, an assessment and recommendation on physical activity, and advice on managing potential psychosocial issues by the multidisciplinary team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: Self-management
Description: Each pamphlet given to the patients addresses one of the 7 most commonly-reported symptoms (sleep difficulties, fatigue, neuropathy, pain, anxiety, depression, and fear of cancer progression) observed in Hong Kong patients with advanced or metastatic cancer, plus two on lifestyle recommendations (physical activity and eating well). All pamphlets are developed based on the self-management framework.
Study: NCT05403827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-161
Description: K-161 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle Solution
Study: NCT06413680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10597
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10597
Description: Administered as an intravenous (IV) infusion
Study: NCT05726838

Intervention type: OTHER
Intervention: Inclisiran
Description: There is no treatment allocation. Patients administered inclisiran by prescription will be enrolled. The patients will receive inclisiran therapy as per the approved label and Belgian reimbursement conditions.
Study: NCT05776277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iltamiocel
Description: Single external anal sphincter (EAS) injection of 300 x 10\^6 cells.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control is the vehicle solution used for the study product.
Study: NCT06506721

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double ballon device, Cook
Description: Cook double balloon will be introduced transcervically. The double balloon will be inflated with sterile 0-9% saline solution (maximum 80 ml in each balloon of the double device), then the catheter will be fixed with a tape at the women's thigh without traction. The catheter will remain in place until spontaneously expelled or start of active labour.~If neither happens, the device will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hygroscopic cervix dilators, Dilapan-S
Description: A maximum number of 5 hygroscopic cervical dilator rods will be inserted transcervically, after humidification with sterile 0.9% saline solution. They will be fixed in this position by inserting a humidified compress into the vagina. They will remain in place until spontaneously expelled or until start of active labour.~In neither happens, the devices will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed.
Study: NCT05953480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Redasemtide
Description: Lyophilized white powder reconstituted in 0.9% saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Redasemtide
Description: Lyophilized white powder reconstituted in 0.9% saline for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized white powder reconstituted in 0.9% saline for injection
Study: NCT05639062

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative-based card game
Description: This intervention aims to evaluate the preliminary effects of narrative-based card game intervention on spiritual well-being, hope, anxiety, depressive symptoms, and QoL of childhood cancer patients at postintervention and at 1-, and 3-month follow-up postintervention.
Study: NCT06412549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health care practices and routines
Description: The scope of the project includes a diagnostic visit to participating hospitals, conducted by the coordinating center team, to understand existing protocols related to the management of invasive central nervous system devices (such as intracranial pressure monitoring catheters or external ventricular drains), as well as the physical infrastructure, human resources, and other precautions taken for the prevention and treatment of central nervous system infections. All recommendations in the intervention bundle for patient care will align with the guidelines of the National Health Surveillance Agency (ANVISA) and the best available scientific evidence for preventing infections associated with central nervous system devices.~* Provide the best care for patients with ICP and/or EVD, based on the best available evidence, with regard to the insertion and maintenance of catheters, as well as diagnosis and treatment in the presence of infection.~* Training of the multidisciplinary team.
Study: NCT05353452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurology Based Collaborative Care
Description: Twenty-four week, evidence-based remote collaborative care model initiated around the time of a neurology visit. The collaborative care team roles include the care manager, psychiatrist, and psychologist/social worker who interact with the patient participant and the patient's neurologist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOC Neurological care
Description: Usual neurology care means ongoing, epilepsy provider-recommended clinic visits, prescriptions, testing and referrals from their epilepsy provider. Mental health referrals or prescribing of antidepressants may potentially occur in this group; these types of interventions will be tracked at outcome assessments.
Study: NCT05731804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0417 375 mg; Ritonavir100 mg
Description: SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0417 375 mg; Ritonavir100 mg
Description: SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0417 750 mg; Ritonavir100 mg
Description: SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
Study: NCT00995059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given oral or IV
Study: NCT04920877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infection Prevention
Description: Preventing central catheter-related bloodstream infections in intensive care units
Study: NCT00995059

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo total-body irradiation
Study: NCT05731804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0417 750 mg; Ritonavir100 mg
Description: SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
Study: NCT05625022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lianhua Qingke tablets
Description: Lianhua Qingke tablets: 4 tablets once, three times daily
Study: NCT05510505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD20 monoclonal antibody
Description: 4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: 4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d
Study: NCT04999189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app forDiabetes (Tessera Multimedia, 2020)
Description: Patients will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
Study: NCT06036589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA and BAM8-22
Description: CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle and BAM8-22 application
Description: Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA
Description: CA (tran-cinnamaldheyde) solution (in ethanol 5%) application to a previously determined area on the volar forearm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vehicle
Description: Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm
Study: NCT05834387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EICU Transfer Routine Care
Description: EICU Transfer Routine Care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementing interventions based on a 'health care-family-environment' linkage
Description: Nursing interventions in the experimental group The interventions were based on the health care-family-environment linkage
Study: NCT05805618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Norovirus Hexavalent Vaccine
Description: To prevent acute gastroenteritis caused by norovirus of genotypes GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: matching placebo for Recombinant Norovirus Hexavalent Vaccine / KH002
Study: NCT05316935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa
Description: Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa
Description: Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: 2.5mg po qd and no more than 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: 2.5mg po qd and no more than 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diane-35
Description: Periodic use. Patients will receive one pill po qd for 21 days, and next period should be started after 7 days.
Study: NCT06170996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based behavioral parent training (I-BPT)
Description: Internet-based behavioural parent training in a group format, 8 sessions over 2 months, delivered by a systematically trained and supervised therapist.
Study: NCT06196866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: The control group will develop only conventional treatment for the whole trial (weeks 1-24), consisting of carrying out daily routine activities and/or 1 session/week of physiotherapy (which includes manual therapy, active exercises of repetition of functional movements, walking, stairs and stretching) with a time of 45 minutes/session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nintendo Ring Fit Adventure + Conventional Therapy
Description: In the exergaming group 1, the intervention will be 12 weeks (weeks 1-12) with a frequency of 1 session/week and with a time of 45 minutes/session, in addition to the users' conventional therapy. The training will be a first 5 minutes warm-up (composed of joint mobility and global stretching), 35 min of exergaming training (working on the participants' gait, stability and global muscle strength) and last 5 minutes of cooling down (composed of breathing exercises, joint mobility and global stretching) in each session. The therapist will choose in each session different exercises from each of these 4 sections:~Jogging: Begginia or Transient Temple.~Minigames: Squat Goals, Squattery Wheel, Gluting Gallery, Thigh Rider, Bank Balance or Dreadmill.~Lower Limbs Training: Knee Lift or Hip Lift.~Yoga: Tree Pose or Chair Pose.
Study: NCT05316935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diane-35
Description: Periodic use. Patients will receive one pill po qd for 21 days, and next period should be started after 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET
Description: 500mg po tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET
Description: 500mg po tid
Study: NCT06139627

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection
Study: NCT06196866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit + Conventional Therapy
Description: In the exergaming group 2, the intervention will be 12 weeks (weeks 1-12) with a frequency of 1 session/week and with a time of 45 minutes/session, in addition to the users' conventional therapy. The training will be a first 5 minutes warm-up (composed of joint mobility and global stretching), 35 min of exergaming training (working on the participants' gait, stability and global muscle strength) and last 5 minutes of cooling down (composed of breathing exercises, joint mobility and global stretching) in each session. The therapist will choose in each session different exercises from each of these 4 sections:~Aerobics: Basic Run or Hula Hoop.~Strength Training: Rowing Squat, Single-Leg Extension, Sideways Leg Lift or Single-Leg Twist.~Balance Games: Ski Jump, Balance Bubble, Table Tilt or Penguin Slide.~Yoga: Chair or Standing Knee.
Study: NCT06139627

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive GA assessment summary and assessment-based recommendations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Complete GA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Geriatric Assessment
Description: Complete GA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06032013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (PROMs)
Description: The program is multidisciplinary with the following components:~* Medical assessment~* Physical training and counselling on physical activity~* Identification and control of risk factors~* Nutritional assessment and counselling~* Psychological assessment and intervention~* Education and information
Study: NCT05847985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS using electric currents to modulate underlying neurons
Study: NCT05980715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1inhibitor
Description: The PD-1 monoclonal antibody was the same as the neoadjuvant therapy before surgery, and the postoperative level was maintained at Q3\*6.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy
Description: According to the guidelines, concurrent chemoradiotherapy is required, and carboplatin (50mg/m2) plus concurrent radiotherapy or cisplatin (30mg/m2) plus concurrent radiotherapy is optional.
Study: NCT05284682

Intervention type: DIAGNOSTIC_TEST
Intervention: Right hearted catheterization
Description: Right hearted catheterization and collection of blood sampels in the coronary sinus, arterial blood and central venous blood for analysis of energy substrate metabolites.

Intervention type: DIAGNOSTIC_TEST
Intervention: Right hearted catheterization
Description: Right hearted catheterization and collection of blood sampels in the coronary sinus, arterial blood and central venous blood for analysis of energy substrate metabolites.
Study: NCT05090319

Intervention type: DIAGNOSTIC_TEST
Intervention: complete blood count
Description: Complete blood count will be performed on the patient. Accuracy of micro-hematology analyzer will be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: complete blood count
Description: Complete blood count will be performed on the patient. Accuracy of micro-hematology analyzer will be assessed.
Study: NCT03530709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: videoconferencing
Description: Parents/caregivers will use smartphones to videoconference in their SCC provider during PCP visits
Study: NCT06294210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app and wrist-worn monitor
Description: A mobile app was developed based on students feedback about their wellbeing needs gathered in a previous study through focus groups, surveys and design activities. This app includes features for students to track wellbeing habits, enter goals, access evidence-based resources related to their wellbeing topics of interest, and see heart rate variability summary metrics. These metrics will stream via bluetooth from the wrist-worn wearable device that has been developed at the Royal College of Surgeons in Ireland. This device includes a PPG sensor, charging port, and light indicator. There is no screen, so all data will be displayed through the mobile app.
Study: NCT05514808

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education modules
Description: Nutrition education modules on sports nutrition and dietary supplements over a period of 4 weeks (1 module/week)
Study: NCT06548893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group acceptance and commitment therapy (ACT)
Description: Group psychotherapy based on ACT + EPR